DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation.

Author(s): Jackson KC 2nd, Nahoopii R, Said Q, Dirani R, Brixner D

Affiliation(s): Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA.

Publication date & source: 2007-04, J Occup Environ Med., 49(4):453-60.

Publication type: Research Support, Non-U.S. Gov't

INTRODUCTION: An employer-based cost-benefit analysis for varenicline versus bupropion was conducted using clinical outcomes from a recently published trial. METHODS: A decision tree model was developed based on the net benefit of treatment to produce a nonsmoker at 1 year. Sensitivity analyses were conducted based on quit rates with placebo and varenicline and the cost of varenicline. RESULTS: Estimated 12-month employer cost savings per non-smoking employee were $540.60 for varenicline, $269.80 for bupropion SR generic, $150.80 for bupropion SR brand, and $81.80 for placebo. Varenicline was more cost beneficial than placebo, which had quit rates of 16.9% or less. The quit rate with varenicline would have to be <or=16.9% to lose cost benefit over bupropion SR generic. CONCLUSIONS: The economic benefit of varenicline is improved over bupropion, despite the increased initial cost of varenicline.

Page last updated: 2007-05-03

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017